Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06762496

A New Tool to Promote Patient's Engagement in Their Healthcare Process

Women diagnosed with early-stage breast cancer need to make a decision about the therapeutic treatment to undertake. Since multiple factors can influence this decision, it is necessary to develop a decision-making support tool to assist them in making this choice.

Main Objective: To develop a decision-making support tool for determining the treatment to undertake for women diagnosed with early-stage breast cancer and test its effectiveness on an experimental group.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

European Institute of Oncology

Milan, Italy, 20141

Location status: Recruiting

About this study

Women with any type of early breast cancer (0-2A stages) will be recruited at Istituto Europeo di Oncologia (IEO). 170 patients with early breast cancer and 30 clinicians involved in the present project will directly benefit from better-provided care, an increase in patients' knowledge and management of their oncological symptoms, an improved patient-and-doctor relationship, and a reduction of hospital economic costs.

Our interdisciplinary team will include breast cancer patients, oncologists, surgeons, psychologists, radiologists, , and nurses. All members of our team will play an active role in the most important phases of our data-driven project development cycle. A patient-centered approach will allow us to ensure their active participation from the design phase to the dissemination phase of the project.

This present research project will be based on two different prospective studies: a first study based on patients already treated for breast cancer and a second study with patients newly diagnosed with early breast cancer.

Semi structured interviews will be used in the first study, while newly diagnosed women in the second study will be asked to fill in an online battery of questionnaires in three different times (T0: one week after the first consultation; T1: a month later the first medical consultation; T2: three months later the first medical consultation) to assess the possible impact of using the Patient Decision Aids (PDA) on the doctor-patient communication and shared decision-making (SDM) process.

This project will follow a multi-step approach and will be therefore divided into different developmental phases, within which specific objectives will need to be reached in order to move forward.

Assessment measures throughout the protocol include: AttrakDiff; SUS, a 38-item specific questionnaire that measures satsifaction with PDA, PHQ-9, STAI, SDMQ9, Distress thermometer, EORTC-QLQ.C30, EORT-QLQ-BR23. Any further material used for qualitative assessment will be be made available upon reasonable request.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • be 18 or older;
  • have received/receive diagnosis of resectable breast cancer in the early stage;
  • women treated or who will undergo oncological treatment for early breast cancer;
  • demonstrate the absence of psychopathological features.
  • be willing and able to provide written informed consent/assent for the trial

Exclusion criteria

  • breast cancer patients who showed physical or psychological issues, as well as cognitive impairments that prohibited their participation in this type of study;
  • neurological or psychiatric disorders that may compromise the patients' ability to take part in the study.
  • Distant metastases from breast cancer or locally advanced/unresectable disease
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Treatment and study plan

Healthcare professionals

Other

healthcare professionals (HCPs) targeted, including team members: we will involve 30 physicians (who are involved in the process of care towards patients with early breast cancer (10 oncologists, 10 breast surgeon, and 10 breast radiologists specifically) for the semi-structured interviews

Patients PDA group

Other

Participants will receive via mail the final version of the PDA and a Qualtrics link with a battery of questionnaires

Patients control group

Other

Participants will receive only the online link with the battery of questionnaires

Primary outcomes

  1. Development of an ad hoc Patient Decision Aid (PDA)

    Time frame: 3 months

    Patients in the Intervention group will receive via mail the final version of the PDA and a battery of questionnaires.

    Patients in the Control group will receive only the online link with the battery of questionnaires.

    In both the experimental and the control group, questionnaires will be administered one week after the first medical consultation (T0), one month later the first medical consultation (T1), and three months later the first medical consultations (T2).

    The difference between T1 and T0 and T2 and T0 will be calculated for each endpoint.

Study contacts

Contact information is provided by the study sponsor or research team.

Gabriella Pravettoni

CONTACT

[email protected]

0039 02 57489731

Sponsors and collaborators

Lead sponsor

European Institute of Oncology

Other

Registry information

Official study title

Development and Testing of a Patient's Decision Aid for Early Breast Cancer: a New Tool to Promote Patient's Engagement in Their Healthcare Process

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jan 7, 2025
Registry last updated
Nov 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.